Reports say scientists are working on the formulation of a new drug that may slow down diseases like Parkinson's, Alzheimer's and Huntington's.
Professor Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine and colleagues teamed up with chemists, biotechnologists and 3-D modelists to "build" the new drug, L803-MTS.
AdvertisementThe drug locks onto the GSK3 protein, which plays a causative role in insulin resistance and Type II diabetes, rendering it harmless and unable to wreak havoc inside the body.
Prof. Eldar-Finkelman said: "Ours is the first lab that showed the importance of GSK3 as a target in Type II diabetes, and was among the first to introduce a specific inhibitor against the GSK3.
"Our approach became so popular that today many pharmaceutical companies, big and small, are competing to work on a GSK3 inhibitor."
Prof. Eldar-Finkelman believes the new compound will be a lead one for treating central nervous system (CNS) disorders, "because it was based on rational drug design. We started from scratch and thought through the design of a specific compound that would be safe and effective. Our aim is to slow the progression of CNS diseases, but the new drug might also be used as a preventative therapy."
Recent research findings on the L803-MTS drug have been published in the Journal of Molecular Biology (2008) and Current Pharmaceutical Design (2009).
PScientists Identify New Cellular Pathway That Could Explain Link Between Alcohol and Cancer Spread Steep Rise In Hospital Admissions For Obesity In England M
You May Also Like